Key result
Higher baseline Angpt-2 is linked to incident CVD in recent-onset rheumatoid arthritis.
Why the study?
Are serum levels of endothelial cell activation markers (VEGF, sVCAM-1, Angpt-2) associated with inflammation, disease activity, radiological progression, and future cardiovascular disease in patients with recent-onset rheumatoid arthritis?
Cohort (n=176)
Are serum levels of endothelial cell activation markers (VEGF, sVCAM-1, Angpt-2) associated with inflammation, disease activity, radiological progression, and future cardiovascular disease in patients with recent-onset rheumatoid arthritis?
In patients with early rheumatoid arthritis, elevated baseline levels of Angiopoietin-2 correlate with inflammation and disease activity, and may predict the long-term development of cardiovascular disease.
May flag higher long-term CVD risk in early RA; leaves open incremental value over standard predictors and any therapeutic role.
OBJECTIVE: To investigate whether serum levels of endothelial cell activation markers in early RA patients can serve as biomarkers for inflammation and disease activity, and are associated with radiological progression and development of cardiovascular disease (CVD). METHODS: Serum levels of VEGF, soluble vascular cell adhesion molecule (sVCAM)-1 and angiopoietin-2 (Angpt-2) were measured by ELISA in 176 patients with recent-onset RA, at the time of diagnosis and after 2 years. Markers of inflammation and disease activity were assessed, as well as radiological damage of hands and feet, at diagnosis and after 2 years. Prevalence of CVD of all patients after 12.5 years disease duration was retrieved from medical records. RESULTS: Patients with RA had higher levels of VEGF and Angpt-2 at disease onset compared with healthy controls, which correlated with markers of inflammation, but were not predictive of radiological progression after 2 years. Angpt-2 levels, moreover, significantly correlated with measures of disease activity. Nearly 18% of RA patients developed CVD after an average of 12.5 years of disease, and these patients had a significantly higher level of Angpt-2 at the onset of RA compared with patients who did not develop CVD. CONCLUSIONS: In early RA, markers of endothelial activation are highly correlated with inflammation and disease activity, but not with radiological progression. Angpt-2 could be predictive for the development of CVD since Angpt-2 levels were significantly higher in CVD patients than in non-CVD patients.
No takes yet. Share an insight, caveat, or question.
Westra et al. (2010) conducted a cohort in recent-onset rheumatoid arthritis (n=176). Angiopoietin-2 (Angpt-2) levels vs. Patients who did not develop cardiovascular disease was evaluated on Development of cardiovascular disease (CVD). Baseline Angpt-2 levels were significantly higher in the nearly 18% of recent-onset rheumatoid arthritis patients who developed cardiovascular disease over 12.5 years compared to those who did not.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: